TICKERNERD
Menu
PBYIPBYIHealthcare · Biotechnology

PBYI Stock Forecast: Puma Biotechnology, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$8.83
+1.38% on the day

The 1 Wall Street analysts covering Puma Biotechnology, Inc. hold a median 12-month price target of $6 — -32.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 15 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$455.8M
Ticker Nerd rank
99 / 100
Median analyst target
$6.00
Analysts covering
1
Total return, dividends reinvested
1W
−0.9%
1M
+6.6%
YTD
+48.4%
1Y
+66.0%
From 52W high
−0.9%
From 52W low
+103.5%
$4.34
$8.91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PBYI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Puma Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Quality
99
Momentum
96
Volatility
91
Issuance
85
Accruals
76
Revisions
65
Size
55
Growth
30

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (30): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PBYI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PBYI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$5.00$6.00$7.00$8.00$9.00Oct 25Jan 26Apr 26Jul 26PBYIHigh $6.00Median $6.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Low $6.00Median $6.00High $6.00

The green dot is the last close — the median target sits −32.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026TD CowenMaintainsHold$5.00 → $6.00
28 Feb 2025HC Wainwright & Co.ReiteratesBuy$7.00
28 Feb 2025HC Wainwright & Co.ReiteratesBuy—
23 Dec 2024HC Wainwright & Co.ReiteratesBuy—
20 Nov 2024HC Wainwright & Co.ReiteratesBuy—
8 Nov 2024HC Wainwright & Co.ReiteratesBuy—
2 Aug 2024HC Wainwright & Co.ReiteratesBuy—
26 July 2024HC Wainwright & Co.ReiteratesBuy—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
3 June 2024HC Wainwright & Co.ReiteratesBuy—
20 May 2024HC Wainwright & Co.ReiteratesBuy—
3 May 2024HC Wainwright & Co.ReiteratesBuy—
1 Mar 2024HC Wainwright & Co.MaintainsBuy—
13 Feb 2024HC Wainwright & Co.ReiteratesBuy—
20 Sept 2023HC Wainwright & Co.ReiteratesBuy—
4 Aug 2023HC Wainwright & Co.ReiteratesBuy—
5 June 2023HC Wainwright & Co.ReiteratesBuy—
5 May 2023HC Wainwright & Co.ReiteratesBuy—
6 Mar 2023HC Wainwright & Co.ReiteratesBuy—
31 Aug 2022HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBYI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PBYI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+22.2%
Analysts raising
1
Analysts cutting
0
Fundamentals

Puma Biotechnology, Inc. (PBYI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.0×

Cheaper than 44% of US stocks

Price / sales
2.0×

Cheaper than 54% of US stocks

Price / book
3.3×

Cheaper than 33% of US stocks

EV / EBITDA
9.1×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
7.8%

Higher than 47% of US stocks

Earnings growth (YoY)
39.9%

Higher than 72% of US stocks

Gross margin
77.9%

Higher than 89% of US stocks

Operating margin
13.4%

Higher than 70% of US stocks

Net margin
11.6%

Higher than 73% of US stocks

Returns & dividend
Return on equity
22.0%

Higher than 83% of US stocks

Return on assets
9.8%

Higher than 92% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PBYI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PBYIPuma Biotechnology, Inc.$455.8M
99
CABACabaletta Bio, Inc.$448.4M
28
QTTBQ32 Bio, Inc.$450.9M
86
OCGNOcugen, Inc.$457.0M
24
RZLTRezolute, Inc.$440.2M
34
DNAGinkgo Bioworks Holdings, Inc.$439.8M
49
LRMRLarimar Therapeutics, Inc.$460.4M
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Puma Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PBYI news & analysis

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Zacks Investment Research · 12 Aug 2026neutral

Zacks Investment Research published an article examining whether Puma Biotechnology (PBYI) is currently a great value stock. The piece explains that Zacks focuses on its Rank system, which emphasizes earnings estimates and estimate revisions, while also monitoring value, growth, and momentum trends to identify strong picks.

Why it matters — PBYI watchers would care because the article assesses the company's value-stock appeal using Zacks' earnings-estimate and trend-based methodology, which could inform how the stock is viewed by investors.

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Zacks Investment Research · 7 Aug 2026positive

Puma Biotechnology beat Q2 earnings and revenue estimates, raised its 2026 guidance, and noted rising Nerlynx sales along with upcoming milestones for its alisertib study.

Why it matters — PBYI watchers would care because the company exceeded expectations this quarter and raised its forward outlook, suggesting improved operational momentum.

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Puma Biotechnology held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's financial results and operational updates for the quarter.

Why it matters — The earnings call provides direct insight from management on PBYI's quarterly performance and strategic outlook.

Puma Biotechnology Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Puma Biotechnology reported second-quarter 2026 total revenue of $56.5 million, comprising $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net income of $8.2 million, or $0.16 per diluted share, compared with a net loss of $3.8 million in the first quarter.

Why it matters — A PBYI watcher would care because the company swung from a first-quarter net loss to second-quarter profitability with higher revenue.

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Zacks Investment Research · 7 Aug 2026positive

Puma Biotechnology reported Q2 earnings of $0.19 per share, exceeding the Zacks Consensus Estimate of $0.10 per share and compared with $0.15 per share a year ago. Revenue for the quarter also topped estimates.

Why it matters — The quarterly results beat analyst expectations on both earnings and revenue, providing a fresh data point for PBYI watchers assessing recent performance.

FAQ

Frequently asked questions about PBYI stock

What is the PBYI stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Puma Biotechnology, Inc. have a median 12-month price target of $6, with estimates ranging from $6 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PBYI stock a buy right now?

Of the 1 analysts covering Puma Biotechnology, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Puma Biotechnology, Inc. 99 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PBYI?

As at 15 Aug 2026, Puma Biotechnology, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will PBYI stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies -32.0% from the last close, and Ticker Nerd's factor model ranks Puma Biotechnology, Inc. 99 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PBYI stock forecast for 2030?

No analyst covering Puma Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBYI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $6 over the next 12 months.

How has PBYI stock performed over the past year?

Puma Biotechnology, Inc. returned +66.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Puma Biotechnology, Inc. do?

Puma Biotechnology Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies aimed at treating cancer.

What is the latest news on PBYI?

The most recent item we track (Zacks Investment Research, 12 Aug 2026): "Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?". Zacks Investment Research published an article examining whether Puma Biotechnology (PBYI) is currently a great value stock. The piece explains that Zacks focuses on its Rank system, which emphasizes earnings estimates and estimate revisions, while also monitoring value, growth, and momentum trends to identify strong picks.

Company

About Puma Biotechnology, Inc.

Puma Biotechnology Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies aimed at treating cancer. Its primary focus centers on enhancing cancer treatment through advanced pharmaceutical interventions, particularly targeting breast cancer and other tumors that overexpress the HER2 protein. A key product in Puma Biotechnology's portfolio is neratinib, an oral medication designed to inhibit cancer cell proliferation by interfering with the HER2/neu and EGFR kinases. This compound represents a significant stride in oncology, particularly as it's suited for patients with early-stage and metastatic HER2-positive breast cancer. Puma Biotechnology's impact resonates across the healthcare sector, providing groundbreaking therapeutic solutions that address unmet medical needs. Its operational strategies and clinical advancements position it as an influential player in the pharmaceutical and healthcare industries. Founded in 2010 and headquartered in Los Angeles, California, the company continues to contribute to the global cancer treatment landscape through research and strategic partnerships, aiming to improve patient outcomes and redefine standard care protocols in oncology.

CEO Mr. Alan H. Auerbach · 179 employees · United States · https://www.pumabiotechnology.com